The endothelial cell receptor GRP78 is required for mucormycosis pathogenesis in diabetic mice

Mingfu Liu1, Brad Spellberg, Quynh T Phan

  • 1Division of Infectious Diseases, Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, California 90502, USA.

Insights

Glucose-regulated protein 78 (GRP78) is a novel receptor mediating fungal invasion in mucormycosis. Elevated glucose and iron enhance GRP78 expression, increasing infection risk, particularly in diabetic ketoacidosis (DKA).

Area of Science:

  • Mycology
  • Infectious Diseases
  • Cell Biology

Background:

  • Mucormycosis, a severe fungal infection, has a high mortality rate.
  • Angioinvasion is a key characteristic of Mucorales infections.
  • Patients with elevated serum iron, like those with diabetic ketoacidosis (DKA), are highly susceptible.

Purpose of the Study:

  • Identify endothelial cell receptors for Mucorales fungi.
  • Investigate the role of iron and glucose in regulating receptor expression.
  • Understand the mechanism of host-pathogen interaction in mucormycosis.

Main Methods:

  • Identified glucose-regulated protein 78 (GRP78) as a novel host receptor.
  • Utilized human endothelial cells and Rhizopus oryzae, Candida albicans, and Aspergillus fumigatus.
  • Examined the effects of elevated glucose and iron concentrations on GRP78 expression and fungal invasion.
  • Assessed GRP78 expression in DKA mouse models.
  • Evaluated the protective effect of GRP78-specific immune serum in DKA mice.

Main Results:

  • GRP78 mediates invasion and damage of human endothelial cells by Rhizopus oryzae.
  • Elevated glucose and iron enhance GRP78 expression and R. oryzae invasion.
  • DKA mice showed increased GRP78 expression in multiple organs.
  • GRP78-specific immune serum conferred protection against mucormycosis in DKA mice.

Conclusions:

  • GRP78 is a novel host receptor for Rhizopus oryzae, implicated in mucormycosis pathogenesis.
  • Increased GRP78 expression due to high glucose and iron contributes to DKA patient susceptibility.
  • Targeting GRP78 offers a potential therapeutic strategy for mucormycosis.